PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $133863.84 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $257.50.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $133863.84, a 73.85% decline from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $512001.27.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2017 was $39.50, a 571.77% increase from fiscal 2016.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $5.88, a 91.53% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $133863.84 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | $133863.84 10-Q · filed 2025-11-13 | ||||||
| 2024-12-31 | $512001.27 10-K · filed 2026-03-05 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | ||||||
| 2017-12-31 | $39.50 10-K · filed 2018-03-26 | ||||||
| 2017-09-30 | $44.80 10-Q/A · filed 2018-03-26 | $4.48 10-Q · filed 2017-11-08 | |||||
| 2017-06-30 | $262.80 10-Q/A · filed 2018-03-26 | $26.28 10-Q · filed 2017-08-10 | |||||
| 2017-03-31 | $257.50 10-Q/A · filed 2018-03-26 | $25.75 10-Q · filed 2017-05-11 | |||||
| 2016-12-31 | $5.88 10-K · filed 2017-03-30 | ||||||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 | ||||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 | ||||||
| 2015-12-31 | $3.07 10-K · filed 2016-03-30 | ||||||
| 2015-09-30 | $3.07 10-Q · filed 2015-11-12 | ||||||
| 2015-06-30 | $2.86 10-Q · filed 2015-08-12 | ||||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-13 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |